Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder
Findings from this real‑world study of Medicaid beneficiaries indicate that earlier cariprazine use is associated with potential reduction in the substantial humanistic and economic burden of MDD.
Authors
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Anita H. Clayton (ORCID: https://orcid.org/0000-0003-4372-0879)
- Guillaume Germain (ORCID: https://orcid.org/0000-0002-4525-7673)
- Nadia Nabulsi (ORCID: https://orcid.org/0000-0003-0632-6311)
- Prakash S. Masand (ORCID: https://orcid.org/0000-0003-1973-9449)
- Susannah Ripley (ORCID: https://orcid.org/0000-0002-7629-6077)
- Sophie Ma
- Mousam Parikh
- Filmon Haile
Institutions
- AbbVie (United States) (US)
- Duke-NUS Medical School (SG)
- Group for Research in Decision Analysis (CA)
- AbbVie (Japan)
- University of Virginia (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-11-30
- DOI
- https://doi.org/10.1080/13696998.2025.2587412
- Primary Topic
- Mental Health Treatment and Access
- Type
- article
- Field-Weighted Citation Impact
- 0.00